|Articles|March 31, 2004

Atrix granted stay in patent infringement case over LHRH therapy

The U.S. District Court for the Northern District of Illinois has issued an order granting Atrix Laboratories' motion to stay the patent infringement suit filed by TAP Pharmaceutical Products, Inc., Takeda Chemical Industries, Ltd., and Wako Pure Chemical Industries, Ltd., according to an Atrix press release.

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!

Latest CME

Video

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | South Carolina

Scott T. Tagawa, MD, MS, FACP, FASCO; Anusha Madadi, MD

Video

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | West Virginia

Jeremie Calais, MD, PhD; Jason Zhu, MD

Video

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Tennessee

Nasfat Shehadeh, MD; Jeremie Calais, MD, PhD

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Video

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Multimedia

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Multimedia

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Multimedia

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Atrix granted stay in patent infringement case over LHRH therapy

Newsletter

Related Content

Oral testosterone undecanoate shows promising results for first use in the real world

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria

FDA approves androgen inhibitor for metastatic PCa

Latest CME

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | South Carolina

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | West Virginia

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Tennessee

DSUI Urology on the Beach

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Radioligand Therapy 101: The Science Behind the Strategy

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Trending on Urology Times

Community practice experience shows early efficacy, favorable safety with nadofaragene

Sean P. Collins, MD, PhD, outlines the impact of rectal spacers for men with prostate cancer

ORIC-944 shows promise in combination with ARPIs for mCRPC

Suzanne Merrill, MD, on integrating ICIs into clinical practice for NMIBC

Jason Hafron, MD, recaps prostate cancer data from ESMO 2025